Autolus Therapeutics (AUTL) EBITDA Margin (2017 - 2025)

Autolus Therapeutics posted quarterly EBITDA Margin of 373.7% for Q4 2025, up 19232285.0% year-on-year from N/an in Q4 2024, and up 6.71% on a QoQ basis from 400.59% in Q3 2025.

Autolus Therapeutics (AUTL) has 7 years of EBITDA Margin data on file, last reported at 373.7% in Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 19232285.0% year-over-year to 373.7%; the trailing twelve-month figure through Dec 2025 stood at 349.8% (up 183051.0% YoY), and the FY2025 full-year result was 349.8%, up 183245.0% from the prior year.
  • EBITDA Margin for Q4 2025 stood at 373.7%, up from 400.59% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 20932.13% in Q4 2021 and bottomed at 192696.55% in Q4 2024.
  • The 5-year median for EBITDA Margin is 400.59% (2025), against an average of 14224.24%.
  • The widest annual swing landed in 2022, when EBITDA Margin plunged 3871078 bps; it then jumped 19232285 bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 20932.13% in 2021, then tumbled by 228 bps to 26817.47% in 2022, then soared by 53 bps to 12730.54% in 2023, then slumped by 1414 bps to 192696.55% in 2024, then soared by 100 bps to 373.7% in 2025.
  • The last three EBITDA Margin figures came in at 373.7% (Q4 2025), 400.59% (Q3 2025), and 138.36% (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 38.10%
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 18.35%
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 17.24%
10 Autolus Therapeutics - - -1.04 Mn -373.70%

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -373.70%
Sep 30, 2025 -400.59%
Jun 30, 2025 -138.36%
Mar 31, 2025 -657.90%
Dec 31, 2024 -192,696.55%
Mar 31, 2024 -521.11%
Sep 30, 2023 -12,730.54%
Mar 31, 2023 -2,644.74%
Mar 31, 2022 -26,817.47%
Dec 31, 2021 20,932.13%
Sep 30, 2021 17,141.53%
Jun 30, 2021 2,098.94%
Mar 31, 2021 11,893.31%
Dec 31, 2020 -61,163.86%
Sep 30, 2020 6,027.40%
Jun 30, 2020 11,557.68%
Mar 31, 2020 14,075.15%
Dec 31, 2017 -3,861.90%